Cefilavancin Trihydrochloride

N/A

Report date: 2022/05/17 17:51:45
NME

Base Information

Drug NameCefilavancin Trihydrochloride
Drug Alias Namecefilavancinum塞古霉素头孢拉凡星cefilavancinacefilavancin +[7] 
ClassificationSmall molecules > Synthetic peptideSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionCell wall inhibitorsBacterial penicillin-binding protein inhibitorsPeptidoglycan inhibitors
TargetsBacterial penicillin-binding proteinPeptidoglycan
Therapy Area/IndicationsAcute bacterial skin and skin structure infectionsStaphylococcal Skin InfectionsGram-Positive Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTheravance Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesTheravance Biopharma IncR-Pharm Jsc
Inactive CompaniesN/A
Active IndicationsAcute bacterial skin and skin structure infectionsGram-Positive Bacterial Infections
Inactive IndicationsStaphylococcal Skin Infections

Other Information

ATC CodeN/A
Related LinksN/A